EGFR and lung adenocarcinoma: Our results indicated that other than well-known genes such as EGFR, KRAS, and TP53, mutations in other genes involved in relating pathways (as listed in Figure 3B) deserve more attention, and an involvement of these genes might be necessary in the future screening of early stage lung adenocarcinoma.